Opinion

Video

ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

Author(s):

Jason Porter, MD

Key Takeaways

  • Osimertinib significantly improved progression-free survival in unresectable stage III EGFR-mutated NSCLC post-definitive CRT, as shown in the phase 3 LAURA trial.
  • The trial results suggest osimertinib may become a new standard of care for patients with EGFR-mutated NSCLC, enhancing treatment strategies.
SHOW MORE

Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.

Video content above is prompted by the following questions:

  • Discuss the data that was presented at the 2024 ASCO Annual Meeting on the progression-free survival from the phase 3 trial LAURA of osimertinib in patients with unresectable stage III EGFR-mutated NSCLC without progression after definitive CRT.
  • What are your key takeaways from this study and how will it impact the current standard of care for EGFR-mutated NSCLC?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Jorge J. Nieva, MD, Keck School of Medicine
5 experts in this video
5 experts in this video
Related Content
Joshua K. Sabari, MD | Image: NYU Langone
Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey
Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
FDA Approved | Image Credit: © wladimir1804 - stock.adobe.com
June 23rd 2025

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC

Pearl Steinzor
The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
Opdivo Qvantig packaging | Image credit: BMS
June 18th 2025

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

Mary Caffrey
FDA Approved | Image Credit: wladimir1804-stock.adobe.com
June 11th 2025

Taletrectinib Approved for ROS1-Positive NSCLC

Maggie L. Shaw
This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for the same patient population, as well as additional non–small cell lung cancer (NSCLC) indications.
FDA Approved | Image credit: chrisdorney – stock.adobe.com
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

Hayden E. Klein
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Krazati packaging | Image credit: Mirati Therapeutics
March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC

Mary Caffrey
Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo